Drug Profile
VTP 38543
Alternative Names: VTP-38543Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Vitae Pharmaceuticals
- Developer Allergan
- Class Small molecules
- Mechanism of Action Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 14 Sep 2016 Allergan enters into a definitive merger agreement with Vitae Pharmaceuticals
- 01 Sep 2016 Vitae Pharmaceuticals completes a phase II trial in Atopic dermatitis in USA and Canada (NCT02655679)